KR101521484B1 - 메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법 - Google Patents
메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법 Download PDFInfo
- Publication number
- KR101521484B1 KR101521484B1 KR1020147027998A KR20147027998A KR101521484B1 KR 101521484 B1 KR101521484 B1 KR 101521484B1 KR 1020147027998 A KR1020147027998 A KR 1020147027998A KR 20147027998 A KR20147027998 A KR 20147027998A KR 101521484 B1 KR101521484 B1 KR 101521484B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- culture
- lymphocyte
- cell
- memory
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 286
- 210000003071 memory t lymphocyte Anatomy 0.000 title claims abstract description 131
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 354
- 230000004913 activation Effects 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 64
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 41
- 239000011886 peripheral blood Substances 0.000 claims abstract description 24
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 24
- 238000010257 thawing Methods 0.000 claims description 36
- 239000001963 growth medium Substances 0.000 claims description 34
- 230000035755 proliferation Effects 0.000 claims description 26
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 239000007790 solid phase Substances 0.000 claims description 16
- 238000012136 culture method Methods 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 14
- 230000003247 decreasing effect Effects 0.000 abstract description 6
- 239000002609 medium Substances 0.000 description 56
- 239000007788 liquid Substances 0.000 description 46
- 239000006285 cell suspension Substances 0.000 description 43
- 239000000427 antigen Substances 0.000 description 37
- 102000036639 antigens Human genes 0.000 description 37
- 108091007433 antigens Proteins 0.000 description 37
- 230000003321 amplification Effects 0.000 description 33
- 238000003199 nucleic acid amplification method Methods 0.000 description 33
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 30
- 102100033467 L-selectin Human genes 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000012258 culturing Methods 0.000 description 24
- 238000005138 cryopreservation Methods 0.000 description 22
- 102000000588 Interleukin-2 Human genes 0.000 description 19
- 239000000306 component Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000007710 freezing Methods 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 230000008014 freezing Effects 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000003306 harvesting Methods 0.000 description 14
- 238000010899 nucleation Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 12
- 239000002504 physiological saline solution Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000009331 sowing Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 229920001342 Bakelite® Polymers 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101710160107 Outer membrane protein A Proteins 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010079 rubber tapping Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 102000051200 human SELL Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2012-088926 | 2012-04-10 | ||
| JP2012088926A JP6142142B2 (ja) | 2012-04-10 | 2012-04-10 | メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法 |
| PCT/JP2013/002405 WO2013153800A1 (ja) | 2012-04-10 | 2013-04-09 | メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140145585A KR20140145585A (ko) | 2014-12-23 |
| KR101521484B1 true KR101521484B1 (ko) | 2015-06-05 |
Family
ID=49327384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147027998A KR101521484B1 (ko) | 2012-04-10 | 2013-04-09 | 메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP6142142B2 (ja) |
| KR (1) | KR101521484B1 (ja) |
| CN (1) | CN104204195B (ja) |
| HK (1) | HK1205181A1 (ja) |
| WO (1) | WO2013153800A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6424447B2 (ja) | 2014-03-28 | 2018-11-21 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法、及び細胞培養システム |
| KR101922322B1 (ko) | 2014-07-22 | 2018-11-26 | 가부시키가이샤 간멘에키켄큐쇼 | 말초 순환 암세포의 검출 방법 및 검출 장치 |
| KR101984074B1 (ko) | 2015-01-30 | 2019-05-30 | 도요세이칸 그룹 홀딩스 가부시키가이샤 | 세포 배양 방법 및 세포 배양 장치 |
| CN107384859A (zh) * | 2017-09-05 | 2017-11-24 | 四川新生命干细胞科技股份有限公司 | 一种高纯度nk细胞的分离培养方法 |
| US20200277573A1 (en) * | 2017-11-17 | 2020-09-03 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| CN109628396B (zh) * | 2019-01-24 | 2021-03-26 | 清华大学 | 记忆性淋巴细胞群在肝癌治疗中的应用 |
| CN113005081B (zh) * | 2019-12-20 | 2023-12-19 | 苏州依科赛生物科技股份有限公司 | 一种扩增干细胞样记忆性t细胞的培养方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4395644B2 (ja) * | 1999-07-08 | 2010-01-13 | 株式会社リンフォテック | 投与用製剤の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4389039B2 (ja) * | 1998-04-09 | 2009-12-24 | 株式会社リンフォテック | アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット |
| JP4385158B2 (ja) * | 2000-12-04 | 2009-12-16 | 株式会社リンフォテック | 細胞の保存液および該保存液を用いた細胞の保存方法 |
| JP4917201B2 (ja) * | 2000-12-04 | 2012-04-18 | 株式会社リンフォテック | 臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。 |
| EP1347040B1 (en) * | 2000-12-04 | 2006-01-11 | Lymphotec Inc. | Cell-preservation liquid and method of preserving cells by using the liquid |
| PL2613801T3 (pl) * | 2010-09-08 | 2016-12-30 | Zastosowanie komórek T pamięci centralnych przeciwko obcym antygenom do leczenia białaczki/chłoniaka |
-
2012
- 2012-04-10 JP JP2012088926A patent/JP6142142B2/ja active Active
-
2013
- 2013-04-09 CN CN201380018924.8A patent/CN104204195B/zh active Active
- 2013-04-09 WO PCT/JP2013/002405 patent/WO2013153800A1/ja active Application Filing
- 2013-04-09 KR KR1020147027998A patent/KR101521484B1/ko not_active IP Right Cessation
-
2015
- 2015-06-09 HK HK15105468.5A patent/HK1205181A1/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4395644B2 (ja) * | 1999-07-08 | 2010-01-13 | 株式会社リンフォテック | 投与用製剤の製造方法 |
Non-Patent Citations (3)
| Title |
|---|
| Biotherapy, 2009, Vol.23, No.3, p. 257-262 * |
| Cell Immunol.,1991, Vol.133 (1), p. 206-218 * |
| CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, Vol. 7, No. 3, p. 352-359 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104204195A (zh) | 2014-12-10 |
| WO2013153800A1 (ja) | 2013-10-17 |
| JP2013215141A (ja) | 2013-10-24 |
| CN104204195B (zh) | 2017-07-18 |
| KR20140145585A (ko) | 2014-12-23 |
| HK1205181A1 (en) | 2015-12-11 |
| JP6142142B2 (ja) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101521484B1 (ko) | 메모리 t세포를 주성분으로 하는 림프구 세포군의 제조 방법 | |
| JP6869994B2 (ja) | Ｎｋ細胞培養用培地添加キット、及びキットを用いるｎｋ細胞培養方法 | |
| US10463698B2 (en) | Compositions and methods for expansion of embryonic hematopoietic stem cells | |
| EP2788476A1 (en) | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells | |
| KR20080018089A (ko) | 면역치료용 활성화 림프구 제조방법 | |
| EP3000876B1 (en) | Method for preparing nk cells | |
| JP6073417B2 (ja) | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 | |
| JP7144872B2 (ja) | ヒトリンパ球細胞培養用無血清培地 | |
| WO2019069184A2 (en) | EXPANSION AND USE OF EXTENDED NK CELL FRACTIONS | |
| CN114901805B (zh) | 肿瘤浸润淋巴细胞的培养方法及其用途 | |
| CN117043321A (zh) | 一种修饰的肿瘤浸润淋巴细胞及其用途 | |
| Wickström et al. | Expansion of tumor-infiltrating lymphocytes from melanoma tumors | |
| WO2023072813A1 (en) | Methods for expanding natural killer cells (nk cells) | |
| JP7463239B2 (ja) | ナチュラルキラーｔ（ｎｋｔ）細胞を刺激する樹状細胞の製造方法 | |
| EP3634436A2 (en) | Selection and use of umbilical cord cell fractions suitable for transplantation | |
| CN113728231A (zh) | 提供免疫细胞的方法 | |
| CA2659697A1 (en) | Method of proliferating lak cell | |
| WO2024131741A1 (zh) | 一种细胞冻存方法及其用途 | |
| US20220218759A1 (en) | Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product | |
| WO2006011681A1 (ja) | 白血球培養用血液の保存方法、輸送方法、末梢血単核球の保存方法、輸送方法及びそれらを用いた白血球の培養方法 | |
| KR20220160987A (ko) | Nk 세포의 대량 증식 방법 | |
| CN117580944A (zh) | 一种修饰的免疫细胞及其用途 | |
| WO2006011682A1 (ja) | リンパ球の保存及び輸送方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |